In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) unveiled that the first participant was successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently, in Chinese participant with type 2 diabetes mellitus (T2DM)
Both Classic Gs-cAMP/PKA/CREB and Alternative Gs-cAMP/PKA/P38/CREB Signal Pathways Mediate Exenatide-Stimulated Expression of M2 Microglial Markers
Lilly reported producing more than 1.6 times the salable incretin doses in the first half of 2025 compared to the same period in 2024, with plans for significant additional manufacturing expansion [39]
A category of gut peptide hormones, the incretins (glucagon-lie peptide 1
As use grows, so do questions about alcohol
Back Trapp, S, Brierley, DI (29 July 2021) 'Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment' British Journal of Pharmacology
